Trinity Biotech (TRIB)
(Delayed Data from NSDQ)
$2.17 USD
-0.33 (-13.20%)
Updated Aug 28, 2024 03:55 PM ET
After-Market: $2.11 -0.06 (-2.76%) 7:44 PM ET
2-Buy of 5 2
C Value B Growth B Momentum B VGM
Balance Sheet
Fiscal Year End for Trinity Biotech PLC falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 4 | 7 | 26 | 27 | 16 |
Receivables | 14 | 16 | 16 | 23 | 21 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 20 | 23 | 29 | 30 | 32 |
Other Current Assets | 2 | 2 | 2 | 3 | 2 |
Total Current Assets | 39 | 47 | 73 | 83 | 71 |
Net Property & Equipment | 2 | 6 | 6 | 9 | 9 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 2 | 4 | 4 | 4 | 6 |
Intangibles | 16 | 35 | 36 | 34 | 44 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 59 | 92 | 119 | 130 | 131 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 83 | 0 | 0 |
Accounts Payable | 13 | 15 | 15 | 24 | 17 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 2 | 2 | 2 | 2 | 2 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 1 | 0 |
Total Current Liabilities | 15 | 17 | 100 | 27 | 19 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 2 | 5 | 5 | 5 | 7 |
Convertible Debt | 15 | 14 | 0 | 0 | 0 |
Long-Term Debt | 40 | 44 | 0 | 83 | 82 |
Non-Current Capital Leases | 11 | 12 | 14 | 17 | 18 |
Other Non-Current Liabilities | 1 | 2 | 0 | 1 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 83 | 94 | 119 | 133 | 126 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 2 | 2 | 1 | 1 | 1 |
Capital Surplus | 47 | 46 | 16 | 16 | 16 |
Retained Earnings | -49 | -27 | 13 | 11 | 16 |
Other Equity | 1 | 1 | -5 | -5 | -4 |
Treasury Stock | 25 | 25 | 25 | 25 | 25 |
Total Shareholder's Equity | -24 | -2 | 0 | -2 | 5 |
Total Liabilities & Shareholder's Equity | 59 | 92 | 119 | 130 | 131 |
Total Common Equity | -24 | -2 | 0 | -2 | 5 |
Shares Outstanding | 7.60 | 7.60 | 4.10 | 4.10 | 4.80 |
Book Value Per Share | -3.15 | -0.29 | -0.08 | -0.54 | 0.98 |
Fiscal Year End for Trinity Biotech PLC falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 5 | 6 | 4 | 6 | 14 |
Receivables | 17 | 17 | 14 | 15 | 14 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 23 | 23 | 20 | 21 | 23 |
Other Current Assets | 0 | 0 | 2 | 2 | 2 |
Total Current Assets | 46 | 46 | 39 | 44 | 53 |
Net Property & Equipment | 4 | 3 | 2 | 2 | 2 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 2 | 2 | 2 | 2 | 1 |
Intangibles | 42 | 39 | 16 | 16 | 16 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 94 | 90 | 59 | 64 | 72 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 23 | 21 | 13 | 11 | 13 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 2 | 2 | 2 | 2 | 2 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 26 | 23 | 15 | 13 | 15 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 4 | 3 | 2 | 2 | 2 |
Convertible Debt | 15 | 15 | 15 | 14 | 14 |
Long-Term Debt | 66 | 59 | 40 | 40 | 40 |
Non-Current Capital Leases | 10 | 10 | 11 | 11 | 12 |
Other Non-Current Liabilities | 3 | 1 | 1 | 2 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 124 | 113 | 83 | 81 | 83 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 2 | 2 | 2 | 2 | 2 |
Capital Surplus | 50 | 50 | 47 | 47 | 47 |
Retained Earnings | -58 | -51 | -49 | -42 | -36 |
Other Equity | 1 | 1 | 1 | 1 | 1 |
Treasury Stock | 25 | 25 | 25 | 25 | 25 |
Total Shareholder's Equity | -29 | -23 | -24 | -17 | -11 |
Total Liabilities & Shareholder's Equity | 94 | 90 | 59 | 64 | 72 |
Total Common Equity | -29 | -23 | -24 | -17 | -11 |
Shares Outstanding | 7.60 | 7.60 | 7.60 | 7.60 | 7.60 |
Book Value Per Share | -3.87 | -3.01 | -3.15 | -2.30 | -1.50 |